Get the Stockscreener App
2.37
2.07%
-0.05
After Hours:
2.45
0.08
+3.38%
Reshape Lifesciences Inc stock is traded at $2.37, with a volume of 76,819.
It is down -2.07% in the last 24 hours and down -64.89% over the past month.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
See More
Previous Close:
$2.42
Open:
$2.4
24h Volume:
76,819
Relative Volume:
0.03
Market Cap:
$3.28M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.0611
EPS:
-38.77
Net Cash Flow:
$-17.45M
1W Performance:
-0.42%
1M Performance:
-64.89%
6M Performance:
-97.98%
1Y Performance:
-99.28%
1-Day Range:
$2.35
$2.443
1-Week Range:
$2.35
$2.59
52-Week Range:
$2.23
$414.99
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Name
Reshape Lifesciences Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare RSLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
2.37 | 3.28M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
134.44 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.32 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.28 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.39 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.79 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Reshape Lifesciences Inc Stock (RSLS) Latest News
ReShape Lifesciences boosts stockholders’ equity above Nasdaq minimum - Investing.com
ReShape Lifesciences Raises Equity to Avoid Delisting - TipRanks
ReShape Lifesciences Stock Soars On Distribution Agreement With Recon Supply, Draws Retail Applause - MSN
Reshape Lifesciences Stock Price, Quotes and Forecasts | NASDAQ:RSLS - Benzinga
ReShape Lifesciences signs distribution deal with Recon Supply By Investing.com - Investing.com Canada
ReShape Lifesciences (RSLS) Stock Skyrockets Over 30% in Highly Volatile Session - Daily Chhattisgarh News
ReShape Lifesciences (RSLS) Signs Exclusive U.S. Distribution Deal | RSLS Stock News - GuruFocus
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets - GlobeNewswire
ReShape Secures Exclusive Distribution Rights to 18M Veteran Healthcare Market with Recon Supply Deal - Stock Titan
Global Weight-Loss Devices Market: Top Devices, Growth Factors - openPR.com
ReShape Lifesciences Stock Slumps As Company Prices Public Offering At Significant Discount: Retail Holds On To Optimism - Asianet Newsable
ReShape Lifesciences Stock Slumps As Company Prices Public Offering At Significant Discount: Retail Holds On To Optimism By Stocktwits - Investing.com India
ReShape Lifesciences Prices $2.6 Million Share Offering - marketscreener.com
Crude Oil Moves Higher; Graham Shares Surge After Q4 Results - Benzinga
ReShape Lifesciences Announces Public Offering Pricing - TipRanks
ReShape Lifesciences prices public stock offering By Investing.com - Investing.com South Africa
ReShape Lifesciences prices public stock offering - Investing.com
SEC Form 424B5 filed by ReShape Lifesciences Inc. - Quantisnow
ReShape Lifesciences sets share price at $2.50 in public offering By Investing.com - Investing.com Canada
ReShape Lifesciences (RSLS) Announces Public Offering Pricing | - GuruFocus
Why Is ReShape Lifesciences Stock (RSLS) Down 45% Today? - TipRanks
ReShape Lifesciences (RSLS) Announces Public Offering Pricing | RSLS Stock News - GuruFocus
ReShape Lifesciences® Announces Pricing of Public Offering of Common Stock Raising Approximately $2.6 Million - Nasdaq
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering - GlobeNewswire
ReShape Lifesciences Prices 1M Share Public Offering at $2.50 Per Share, Raising $2.6M for Weight Loss Solutions - Stock Titan
Reshape Lifesciences Stock Slumps As Company Prices Public Offering At Significant Discount: Retail Holds On To Optimism - MENAFN.com
Small Cap Stocks To Keep An Eye OnJune 3rd - MarketBeat
SEC Form 424B3 filed by ReShape Lifesciences Inc. - Quantisnow
ReShape Lifesciences achieves EU and UK medical device certification By Investing.com - Investing.com South Africa
ReShape Lifesciences And Kiora Pharma Impress Investors, Dollar General Uplifts Outlook - Finimize
ReShape Lifesciences Stock Soars On Regulatory Certification For Medical Devices In EU, UK: Retail Eyes Fair Valuation - Asianet Newsable
Why ReShape Lifesciences Stock Is Soaring Today: Key Drivers Behind Weight-Loss Company's Surge - Benzinga
ReShape Lifesciences Receives EU Certification for Product Portfolio; Shares Jump - marketscreener.com
ReShape Lifesciences Stock Soars On Regulatory Certification For Medical Devices In EU, UK: Retail Eyes Fair Valuation By Stocktwits - Investing.com India
ReShape Lifesciences (RSLS) Stock Skyrockets Over 62% in Morning Trading Frenzy - Daily Chhattisgarh News
ReShape Lifesciences (RSLS) Achieves Key European and UK Certifications | RSLS Stock News - GuruFocus
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio - The Manila Times
ReShape Lifesciences Achieves EU MDR and UKCA Certification for Medical Devices, Enhancing Patient Safety and Market Access in Europe - Nasdaq
ReShape Lifesciences achieves EU and UK medical device certification - Investing.com
ReShape Lifesciences Beats 2027 Deadline: Gains Crucial EU MDR Certification While Others Still Wait - Stock Titan
RSLS stock touches 52-week low at $4.03 amid market challenges By Investing.com - Investing.com South Africa
RSLS stock touches 52-week low at $4.03 amid market challenges - Investing.com India
ReShape Lifesciences Faces Nasdaq Delisting Notice - TipRanks
ReShape Lifesciences Announces Equity Distribution Agreement - TipRanks
ReShape Lifesciences announces merger progress By Investing.com - Investing.com South Africa
ReShape Lifesciences Announces Merger with Vyome Therapeutics - TipRanks
ReShape Lifesciences announces merger progress - Investing.com
ReShape Lifesciences (NASDAQ:RSLS) Raised to Hold at Wall Street Zen - Defense World
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update - GlobeNewswire
RSLS stock touches 52-week low at $5.5 amid market challenges - Investing.com
ReShape Lifesciences reports Q1 EPS $18.98 vs. ($135.37) last year - TipRanks
Reshape Lifesciences Inc Stock (RSLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):